1
|
|
2
|
Yu KK, Aguilar K, Tsai J, Galimidi R, Gnanapragasam P, Yang L, Baltimore D. Use of mutated self-cleaving 2A peptides as a molecular rheostat to direct simultaneous formation of membrane and secreted anti-HIV immunoglobulins. PLoS One 2012; 7:e50438. [PMID: 23209743 PMCID: PMC3508920 DOI: 10.1371/journal.pone.0050438] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2012] [Accepted: 10/22/2012] [Indexed: 01/21/2023] Open
Abstract
In nature, B cells produce surface immunoglobulin and secreted antibody from the same immunoglobulin gene via alternative splicing of the pre-messenger RNA. Here we present a novel system for genetically programming B cells to direct the simultaneous formation of membrane-bound and secreted immunoglobulins that we term a "Molecular Rheostat", based on the use of mutated "self-cleaving" 2A peptides. The Molecular Rheostat is designed so that the ratio of secreted to membrane-bound immunoglobulins can be controlled by selecting appropriate mutations in the 2A peptide. Lentiviral transgenesis of Molecular Rheostat constructs into B cell lines enables the simultaneous expression of functional b12-based IgM-like BCRs that signal to the cells and mediate the secretion of b12 IgG broadly neutralizing antibodies that can bind and neutralize HIV-1 pseudovirus. We show that these b12-based Molecular Rheostat constructs promote the maturation of EU12 B cells in an in vitro model of B lymphopoiesis. The Molecular Rheostat offers a novel tool for genetically manipulating B cell specificity for B-cell based gene therapy.
Collapse
Affiliation(s)
- Kenneth K. Yu
- California Institute of Technology, Pasadena, California, United States of America
- Keck School of Medicine of the University of Southern California, Los Angeles, California, United States of America
| | - Kiefer Aguilar
- California Institute of Technology, Pasadena, California, United States of America
| | - Jonathan Tsai
- California Institute of Technology, Pasadena, California, United States of America
| | - Rachel Galimidi
- California Institute of Technology, Pasadena, California, United States of America
| | | | - Lili Yang
- California Institute of Technology, Pasadena, California, United States of America
| | - David Baltimore
- California Institute of Technology, Pasadena, California, United States of America
- * E-mail:
| |
Collapse
|
3
|
Flisikowska T, Thorey IS, Offner S, Ros F, Lifke V, Zeitler B, Rottmann O, Vincent A, Zhang L, Jenkins S, Niersbach H, Kind AJ, Gregory PD, Schnieke AE, Platzer J. Efficient immunoglobulin gene disruption and targeted replacement in rabbit using zinc finger nucleases. PLoS One 2011; 6:e21045. [PMID: 21695153 PMCID: PMC3113902 DOI: 10.1371/journal.pone.0021045] [Citation(s) in RCA: 120] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2011] [Accepted: 05/17/2011] [Indexed: 01/31/2023] Open
Abstract
Rabbits are widely used in biomedical research, yet techniques for their precise genetic modification are lacking. We demonstrate that zinc finger nucleases (ZFNs) introduced into fertilized oocytes can inactivate a chosen gene by mutagenesis and also mediate precise homologous recombination with a DNA gene-targeting vector to achieve the first gene knockout and targeted sequence replacement in rabbits. Two ZFN pairs were designed that target the rabbit immunoglobulin M (IgM) locus within exons 1 and 2. ZFN mRNAs were microinjected into pronuclear stage fertilized oocytes. Founder animals carrying distinct mutated IgM alleles were identified and bred to produce offspring. Functional knockout of the immunoglobulin heavy chain locus was confirmed by serum IgM and IgG deficiency and lack of IgM(+) and IgG(+) B lymphocytes. We then tested whether ZFN expression would enable efficient targeted sequence replacement in rabbit oocytes. ZFN mRNA was co-injected with a linear DNA vector designed to replace exon 1 of the IgM locus with ∼1.9 kb of novel sequence. Double strand break induced targeted replacement occurred in up to 17% of embryos and in 18% of fetuses analyzed. Two major goals have been achieved. First, inactivation of the endogenous IgM locus, which is an essential step for the production of therapeutic human polyclonal antibodies in the rabbit. Second, establishing efficient targeted gene manipulation and homologous recombination in a refractory animal species. ZFN mediated genetic engineering in the rabbit and other mammals opens new avenues of experimentation in immunology and many other research fields.
Collapse
Affiliation(s)
- Tatiana Flisikowska
- Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany
| | - Irmgard S. Thorey
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| | - Sonja Offner
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| | - Francesca Ros
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| | - Valeria Lifke
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| | - Bryan Zeitler
- Sangamo BioSciences Inc., Richmond, California, United States of America
| | - Oswald Rottmann
- Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany
| | - Anna Vincent
- Sangamo BioSciences Inc., Richmond, California, United States of America
| | - Lei Zhang
- Sangamo BioSciences Inc., Richmond, California, United States of America
| | - Shirin Jenkins
- Sangamo BioSciences Inc., Richmond, California, United States of America
| | - Helmut Niersbach
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| | - Alexander J. Kind
- Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany
| | - Philip D. Gregory
- Sangamo BioSciences Inc., Richmond, California, United States of America
| | - Angelika E. Schnieke
- Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany
- * E-mail:
| | - Josef Platzer
- Pharma Research and Early Development, Roche Diagnostics GmbH, Penzberg, Germany
| |
Collapse
|
4
|
|
5
|
Transgenic non-human animals capable of producing heterologous antibodies. Expert Opin Ther Pat 2005. [DOI: 10.1517/13543776.8.9.1185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Kellermann SA, Green LL. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Curr Opin Biotechnol 2002; 13:593-7. [PMID: 12482519 DOI: 10.1016/s0958-1669(02)00354-3] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Technical advances made in the 1980s and early 1990s resulted in monoclonal antibodies that are now approved for human therapy. Novel transgenic mouse strains provide a powerful technology platform for creating fully human monoclonal antibodies as therapeutics; ten such antibodies have entered clinical trials since 1998 and more are in preclinical testing. Improved transgenic mouse strains provide a powerful technology platform for creating human therapeutics in the future.
Collapse
|
7
|
Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002; 9:152-66. [PMID: 11965235 DOI: 10.1177/107327480200900207] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND The approval of monoclonal antibodies (MAbs) as antibody-targeted therapy in the management of patients with hematologic malignancies has led to new treatment options for this group of patients. The ability to target antibodies to novel functional receptors can increase their therapeutic efficacy. METHODS The authors reviewed improvements in MAb design to enhance their effectiveness over the existing therapeutic MAb currently approved for treating hematologic malignancies. RESULTS Three classes of therapeutic MAbs showing promise in human clinical trials for treatment of hematologic malignancies include unconjugated MAb, drug conjugates in which the antibody preferentially delivers a potent cytotoxic drug to the tumor, and radioactive immunotherapy in which the antibody delivers a sterilizing dose of radiation to the tumor. CONCLUSIONS A better appreciation of how MAbs are metabolized in the body and localized to tumors is resulting in the development of new antibody constructs with improved biodistribution profiles.
Collapse
Affiliation(s)
- Mitchell E Reff
- Molecular Biology and Tumor Immunology Departments, IDEC Pharmaceuticals Corp, San Diego, CA 92191-9080, USA.
| | | | | |
Collapse
|
8
|
Nicholson IC, Zou X, Popov AV, Cook GP, Corps EM, Humphries S, Ayling C, Goyenechea B, Xian J, Taussig MJ, Neuberger MS, Brüggemann M. Antibody Repertoires of Four- and Five-Feature Translocus Mice Carrying Human Immunoglobulin Heavy Chain and κ and λ Light Chain Yeast Artificial Chromosomes. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.163.12.6898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Abstract
We have produced mice that carry the human Ig heavy (IgH) and both κ and λ light chain transloci in a background in which the endogenous IgH and κ loci have been inactivated. The B lymphocyte population in these translocus mice is restored to about one-third of normal levels, with preferential (3:1) expression of human λ over human κ. Human IgM is found in the serum at levels between 50 and 400 μg/ml and is elevated following immunization. This primary human Ab repertoire is sufficient to yield diverse Ag-specific responses as judged by analysis of mAbs. The use of DH and J segments is similar to that seen in human B cells, with an analogous pattern of N nucleotide insertion. Maturation of the response is accompanied by somatic hypermutation, which is particularly effective in the light chain transloci. These mice therefore allow the production of Ag-specific repertoires of both IgM,κ and IgM,λ Abs and should prove useful for the production of human mAbs for clinical use.
Collapse
Affiliation(s)
| | | | | | - Graham P. Cook
- ‡Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom
| | - Elaine M. Corps
- †Laboratory of Molecular Recognition, The Babraham Institute, Babraham, Cambridge, United Kingdom; and
| | - Sally Humphries
- †Laboratory of Molecular Recognition, The Babraham Institute, Babraham, Cambridge, United Kingdom; and
| | | | | | - Jian Xian
- *Laboratory of Developmental Immunology and
| | - Michael J. Taussig
- †Laboratory of Molecular Recognition, The Babraham Institute, Babraham, Cambridge, United Kingdom; and
| | - Michael S. Neuberger
- ‡Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom
| | | |
Collapse
|
9
|
Abstract
Transgenic mice have been created that carry human immunoglobulin heavy and light chain genes in germline configuration and that have the corresponding endogenous genes silenced. The transgenes are either minigene constructs or large, almost authentic, transloci on yeast artificial chromosomes and undergo B-cell-specific DNA rearrangement and hypermutation in the mouse lymphoid tissue. Monoclonal antibodies with good affinities for human antigens have been obtained after immunisation. These mice may be a future source of human antibodies for therapy.
Collapse
Affiliation(s)
- M Brüggemann
- Laboratory of Developmental Immunology and Translocus Therapeutics, Ltd., Babraham Institute, Cambridge, UK.
| | | |
Collapse
|
10
|
Laeeq S, Smith CA, Wagner SD, Thomas DB. Preferential selection of receptor-binding variants of influenza virus hemagglutinin by the neutralizing antibody repertoire of transgenic mice expressing a human immunoglobulin mu minigene. J Virol 1997; 71:2600-5. [PMID: 9060611 PMCID: PMC191380 DOI: 10.1128/jvi.71.4.2600-2605.1997] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
An analysis was made of the neutralizing antibody repertoire, for influenza virus hemagglutinin (HA) of transgenic mice expressing a human immunoglobulin mu (IgH) minigene, by monoclonal antibody (MAb) selection and sequencing of the HA genes of X31 (H3N2 subtype) laboratory variants. Whereas previously reported laboratory variants, selected in ovo with high-affinity murine MAbs of the IgG class, differed from wild-type virus by a single amino acid residue change in one of the major antigenic sites, neutralizing MAbs from transgenic donors selected novel variant viruses with altered receptor-binding specificity and contained residue changes in both the receptor-binding pocket (HA1 225 or HA1 226) and an antigenic site (HA1 135, HA1 145, or HA1 158). Changes in receptor-binding specificities of the variant viruses were confirmed by their resistance to inhibition by horse serum glycoproteins and altered binding to neoglycoproteins. The residue changes in variant virus V-21.2 (HA1 135 G-->R, 225 G-->D) abrogated neutralization by each of the MAbs; nevertheless V-21.2 was recognized by its own selecting MAb in enzyme-linked immunosorbent assay and therefore qualified as an adsorptive mutant rather than an antigenic variant. We consider that a low-affinity neutralizing antibody response may preferentially select for receptor-binding variants of influenza virus HA.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibodies, Viral/genetics
- Antibodies, Viral/immunology
- Antibody Specificity
- Chick Embryo
- Cross Reactions
- Enzyme-Linked Immunosorbent Assay
- Genetic Variation
- Glycoconjugates/immunology
- Hemagglutination Inhibition Tests
- Hemagglutinin Glycoproteins, Influenza Virus/genetics
- Hemagglutinin Glycoproteins, Influenza Virus/immunology
- Humans
- Immunoglobulin mu-Chains/genetics
- Immunoglobulin mu-Chains/immunology
- Influenza A virus/genetics
- Influenza A virus/immunology
- Influenza A virus/metabolism
- Mice
- Mice, Nude
- Mice, Transgenic
- Molecular Structure
- N-Acetylneuraminic Acid/immunology
- Phenotype
- Receptors, Virus/immunology
- Receptors, Virus/metabolism
Collapse
Affiliation(s)
- S Laeeq
- National Institute for Medical Research, London, United Kingdom
| | | | | | | |
Collapse
|
11
|
Brüggemann M, Neuberger MS. Strategies for expressing human antibody repertoires in transgenic mice. IMMUNOLOGY TODAY 1996; 17:391-7. [PMID: 8783501 DOI: 10.1016/0167-5699(96)10025-6] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Repertoires of human antibodies can be created in transgenic mice carrying human immunoglobulin-gene loci in germline configuration. These 'transloci', introduced either as miniloci or as almost locus-sized regions, undergo rearrangement and hypermutation in mouse lymphoid tissue. Here, Marianne Brüggemann and Michael Neuberger review the use of such mice for raising antigen-specific human monoclonal antibodies, as well as their exploitation for studying regulatory aspects of antibody repertoire formation.
Collapse
Affiliation(s)
- M Brüggemann
- Dept of Development and Genetics, Babraham Institute, Cambridge, UK
| | | |
Collapse
|
12
|
Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, Lonberg N. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14:845-51. [PMID: 9631008 DOI: 10.1038/nbt0796-845] [Citation(s) in RCA: 209] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Human immunoglobulin transgenic mice provide a method of obtaining human monoclonal antibodies (Mabs) using conventional hybridoma technology. We describe a novel strain of human immunoglobulin transgenic mice and the use of this strain to generate multiple high-avidity human sequence IgG kappa Mabs directed against a human antigen. The light chain transgene is derived in part from a yeast artificial chromosome clone that includes nearly half of the germline human V kappa region. In addition, the heavy-chain transgene encodes both human mu and human gamma 1 constant regions, the latter of which is expressed via intratransgene class switching. We have used these animals to isolate human IgG kappa Mabs that are specific for the human T-cell marker CD4, have high binding avidities, and are immunosuppressive in vitro. The human Mab-secreting hybridomas display properties similar to those of wild-type mice including stability, growth, and secretion levels. Mabs with four distinct specificities were derived from a single transgenic mouse, consistent with an extensive diversity in the primary repertoire encoded by the transgenes.
Collapse
Affiliation(s)
- D M Fishwild
- Department of Hybridoma Development, GenPharm International, Mountain View, CA 94043, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Abstract
We have introduced human germline-configuration heavy and kappa light chain minilocus transgenes into mice that have been engineered so that their endogenous heavy and kappa light chain loci are inactive. The two human transgenes are inserted by pronuclear microinjection, while the two endogenous mouse genes are disrupted by homologous recombination in embryonic stem cells. The resulting animals contain four unlinked genetic modifications and must rely on the introduced transgenes for the development of the B-cell lineage and for the generation of an antibody repertoire. The heavy chain transgene includes both the human mu and the human gamma 1 constant region gene segments, as well as upstream switch region sequences. Although mouse B cells and human B cells exhibit species-specific differences in the induction of gamma isotype expression, the transgenic mouse B cells appear to undergo regulated switching to human gamma 1 both in vivo and in vitro. This observation defines a subset of the heavy chain constant region that is sufficient for class switching, and implies that the human gamma 1 switch region includes a core of sequence that is functionally homologous to those cis-acting regulatory elements that direct mouse gamma switching.
Collapse
Affiliation(s)
- F A Harding
- GenPharm International, Mountain View, California 94043, USA
| | | |
Collapse
|
15
|
Brandon EP, Idzerda RL, McKnight GS. Targeting the mouse genome: a compendium of knockouts (Part II). Curr Biol 1995; 5:758-65. [PMID: 7583122 DOI: 10.1016/s0960-9822(95)00152-7] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
16
|
Abstract
We have used homologous recombination in ES cells to engineer B cell-deficient mice that are incapable of expressing endogenous immunoglobulin heavy and kappa light chain genes. We find that B cell development in these mutant mice can be rescued by the introduction of human germline-configuration heavy- and kappa light-chain minilocus transgenes. The transgenes rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation in response to antigen stimulation; thus recapitulating both stages of the humoral immune response using human, rather than mouse, sequences. The mice can be immunized; and human sequence, antigen specific, monoclonal antibodies can be obtained using conventional rodent hybridoma technology. These animals are also of interest for studying the normal processes of immunoglobulin gene expression. We discuss the example of heavy chain class switching, which has not been previously observed within an autonomous transgene.
Collapse
Affiliation(s)
- N Lonberg
- GenPharm International Inc., Mountain View, CA 94043, USA
| | | |
Collapse
|
17
|
Wagner SD, Popov AV, Davies SL, Xian J, Neuberger MS, Brüggemann M. The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci. Eur J Immunol 1994; 24:2672-81. [PMID: 7957560 DOI: 10.1002/eji.1830241116] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
An approach to the preparation of antigen-specific human monoclonal antibodies focuses on mice transgenic for human immunoglobulin gene miniloci; the V gene segments in these miniloci undergo productive rearrangement to yield mouse B cells expressing human immunoglobulin (Ig) chains. The general usefulness of this strategy hinges on whether it is feasible to obtain specific, high-affinity antibodies following immunization of such animals with a variety of antigens. To test this, we have investigated the antigen-specific responses in mice which carry human IgH miniloci (constaining just one or two VH segments) instead of a functional mouse IgH locus. Although serum responses were relatively weak, monoclonal antibodies were readily obtained to all immunogens tested (a hapten, foreign proteins and human lymphoma cells). The affinities of two of the hapten-specific (anti-2-phenyl-oxazol-5-one) antibodies were 60 and 160 nM, values intermediate between what is typically obtained in the primary and secondary response of normal mice. Sequence analysis of the rearranged V genes revealed that junctional events made a major contribution to diversity with a considerable amount of apparently non-templated sequence at the V-D and D-J borders. Somatic hypermutation was also evident within the expressed V gene segments of many of the antigen-specific hybridomas. These findings augur well for the general usefulness of the transgenic approach for the isolation of high-affinity human antibodies to a wide range of antigens and suggests that the miniloci need not be particularly large.
Collapse
Affiliation(s)
- S D Wagner
- M.R.C. Laboratory of Molecular Biology, Cambridge
| | | | | | | | | | | |
Collapse
|